Search hospitals > Nevada > Reno
Renown Regional Medical Center
Claim this profileReno, Nevada 89502
Global Leader in Cancer
Global Leader in Lung Cancer
Conducts research for Tumors
Conducts research for Breast Cancer
Conducts research for Adenocarcinoma
281 reported clinical trials
5 medical researchers
Summary
Renown Regional Medical Center is a medical facility located in Reno, Nevada. This center is recognized for care of Cancer, Lung Cancer, Tumors, Breast Cancer, Adenocarcinoma and other specialties. Renown Regional Medical Center is involved with conducting 281 clinical trials across 474 conditions. There are 5 research doctors associated with this hospital, such as John A. Ellerton, Alan K. Ikeda, Lee Schwartzberg, MD, and Garrett Green, MD.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Lung Cancer
Global LeaderStage IV
Stage II
Stage I
Top PIs
John A. EllertonOptumCare Cancer Care at Fort Apache4 years of reported clinical research
Expert in Cancer
Expert in Lung Cancer
135 reported clinical trials
214 drugs studied
Alan K. IkedaAlliance for Childhood Diseases/Cure 4 the Kids Foundation6 years of reported clinical research
Expert in Tumors
Expert in Leukemia
51 reported clinical trials
108 drugs studied
Lee Schwartzberg, MDRenown Regional Medical Centre1 year of reported clinical research
Studies Breast Cancer
Studies Chemotherapy Side Effects
6 reported clinical trials
10 drugs studied
Garrett Green, MDRenown Regional Medical Center8 years of reported clinical research
Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
2 reported clinical trials
4 drugs studied
Clinical Trials running at Renown Regional Medical Center
Breast Cancer
Lung Cancer
Cancer
Non-Small Cell Lung Cancer
Bladder Cancer
Bladder Carcinoma
Prostate Cancer
Gastric Cancer
Tumors
Acute Lymphoblastic Leukemia
Hormone Therapy with or without Radiation
for Breast Cancer
This study is evaluating whether breast conservation surgery and endocrine therapy results in a non-inferior rate of invasive or non-invasive ipsilateral breast tumor recurrence (IBTR) compared to breast conservation with breast radiation and endocrine therapy.
Recruiting2 awards Phase 313 criteria
Giredestrant + Everolimus
for Advanced or Metastatic Breast Cancer
This Phase III, randomized, open-label, multicenter study will evaluate the efficacy and safety of giredestrant plus everolimus compared with the physician's choice of endocrine therapy plus everolimus in participants with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer who have had previous treatment with cyclin-dependent kinase 4/6 inhibitors (CDK4/6is) and endocrine therapy, either in the locally advanced/metastatic or the adjuvant setting.
Recruiting2 awards Phase 37 criteria
Symptom Monitoring
for Young Women on Hormone Therapy
This phase III trial compares the effect of active symptom monitoring and patient education to patient education alone in helping young women with stage I-III breast cancer stay on their hormone therapy medicines. The patient education tool contains interactive weblinks which provide patients with education material about breast cancer and side effects of therapy. Symptom monitoring is a weblink via email or text message with questions asking about symptoms. Hormone therapy for breast cancer can cause side effects, and may cause some women to stop treatment early. Asking about symptoms more often may help women keep taking hormone therapy medicines.
Recruiting1 award N/A13 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Renown Regional Medical Center?
Renown Regional Medical Center is a medical facility located in Reno, Nevada. This center is recognized for care of Cancer, Lung Cancer, Tumors, Breast Cancer, Adenocarcinoma and other specialties. Renown Regional Medical Center is involved with conducting 281 clinical trials across 474 conditions. There are 5 research doctors associated with this hospital, such as John A. Ellerton, Alan K. Ikeda, Lee Schwartzberg, MD, and Garrett Green, MD.